» Articles » PMID: 39449227

Oligonucleotide Therapeutics in Sports? An Antidoping Perspective

Overview
Specialty Pharmacy
Date 2024 Oct 25
PMID 39449227
Authors
Affiliations
Soon will be listed here.
Abstract

Within the last two decades, the European Medicines Agency and the US Food and Drug Administration have approved several gene therapies. One category is oligonucleotide therapeutics, which allow for the regulation of the expression of target genes. Besides already approved therapeutics, there are several preclinical and clinical trials ongoing. The World Anti-Doping Agency prohibits the use of "nucleic acids or nucleic acid analogs that may alter genome sequences and/or alter gene expression by any mechanism" as a nonspecified method at all times. Hence, the administration of nucleic acids or analogs by athletes would cause an Anti-Doping Rule Violation. Herein, we discuss types of oligonucleotide therapeutics, their potential to be misused in sports, and considerations to sample preparation and mass spectrometric approaches with regard to antidoping analysis.

Citing Articles

Oligonucleotide therapeutics in sports? An antidoping perspective.

Parr M, Keiler A Arch Pharm (Weinheim). 2024; 358(1):e2400404.

PMID: 39449227 PMC: 11704058. DOI: 10.1002/ardp.202400404.

References
1.
Song X, Wang X, Ma Y, Liang Z, Yang Z, Cao H . Site-Specific Modification Using the 2'-Methoxyethyl Group Improves the Specificity and Activity of siRNAs. Mol Ther Nucleic Acids. 2017; 9:242-250. PMC: 5675723. DOI: 10.1016/j.omtn.2017.10.003. View

2.
Antony J, Birrer P, Bohnert C, Zimmerli S, Hillmann P, Schaffhauser H . Local application of engineered insulin-like growth factor I mRNA demonstrates regenerative therapeutic potential . Mol Ther Nucleic Acids. 2023; 34:102055. PMC: 10622308. DOI: 10.1016/j.omtn.2023.102055. View

3.
Smith E, Whitty E, Yoo B, Moore A, Sempere L, Medarova Z . Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine. Cancers (Basel). 2022; 14(6). PMC: 8946086. DOI: 10.3390/cancers14061588. View

4.
Houser W, Butterer A, Addepalli B, Limbach P . Combining recombinant ribonuclease U2 and protein phosphatase for RNA modification mapping by liquid chromatography-mass spectrometry. Anal Biochem. 2015; 478:52-8. DOI: 10.1016/j.ab.2015.03.016. View

5.
Studzinska S, Szymarek J, Mazurkiewicz-Beldzinska M . Improvement of serum sample preparation and chromatographic analysis of nusinersen used for the treatment of spinal muscular atrophy. Talanta. 2023; 267:125173. DOI: 10.1016/j.talanta.2023.125173. View